

AUG 11 1997



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

#25

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 15-22  
Rockville, MD 20857

Dear Mr. Wilson:

The attached application for patent term extension of U.S. Patent No. 4,757,057 was filed on July 21, 1997, under 35 U.S.C. § 156. U.S. Patent No. 4,757,057 issued on July 12, 1988 from an application that claimed priority under 35 U.S.C. § 120 to an application that was filed on August 4, 1978. Accordingly, the original expiration date of the patent is July 12, 2005.

The assistance of your Office is requested in confirming that the product identified in the application, NORMIFLO (ardeparin sodium), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Telephone inquiries regarding this communication should be directed to the undersigned at (703) 306-3159.

Karin Tyson  
Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

cc: Burton A. Amernick  
Pollock, Vande Sande & Priddy  
1990 M Street, NW, Suite 800  
PO Box 19088  
Washington DC 20036